The Third International Symposium on Inflammatory Bowel Diseases was held in Jerusalem during September 10-13, 1989. Four hundred physicians and scientists from 25 countries attended the meeting. The symposium was organized into five panels devoted to state of the art reviews of the latest findings and approaches on the etiology, pathogenesis, metabolic implications, clinical assessment of disease activity and the medical management of IBD. Several issues were discussed in debate form. The last panel was dedicated to discussion of three patients with computer assisted active participation of all the attendants. In addition, 03 abstracts were presented as posters, all of which were published in the Book of Abstracts. The organizing committee gratefully acknowledges the contributors who presented their work in clear and concise manner and the participants, whose active part in the discussions contributed to the success of the meeting. The Jerusalem International symposium on Inflammatory Bowel Diseases has become a tradition that will continue with the Fourth Symposium to be convened in September 1993. Joseph Zimmerman, M.D. Daniel Rachmi1ewitz, M.D. LIST OF FIRST AUTHORS Theodore M. Bayless, Michael J. Langman, Johns Hopkins University Department of Medicine, School of Medicine, Queen Elizabeth Hospital, Baltimore, Maryland. Birmingham, England. Michael D. Blackstone, J.E. Lennard-Jones, University of Chicago, St. Mark's Hospital, Chicago, Illinois. City Road, London, England. Charles O. Elson, Division of Gastroenterology, James Lee Madara, The University of Alabama Department of Pathology, at Birmingham, Brigham and Women's Hospital, Birmingham, Alabama. Boston, Massachusetts.
IBD: the present situation and a glimpse of the promised land.- IBD: the present situation and a glimpse of the promised land.- I: Etiology.- Is IBD a genetic disease?.- Glycoprotein structure and ulcerative colitis.- Barrier function of intestinal epithelial tight junctions (TJ).- Are mycobacteria the cause of Crohn's disease?.- Smoking and inflammatory bowel disease.- II: Pathogenesis and experimental models.- Role of platelet activating factor and interleukin I in the pathogenesis of inflammatory bowel disease.- Is there a primary defect in the host defense mechanism in IBD?.- Evidence against a defect in immune host defenses as a primary process in IBD.- Animal models of inflammatory bowel disease.- III: Clinical assessment.- Why the variation in colitic cancer rates from different centres.- Is there any benefit from cancer surveillance in ulcerative colitis?.- Endoscopy in IBD - what has it accomplished?.- The problem of postoperative recurrence of Crohn's disease.- Endoscopic examination of the small bowel in idiopathic inflammatory bowel diseases.- IV: Nutrition and metabolic implications.- Crohn's disease in children and adolescents: diminished growth velocity.- Skeletal complications of inflammatory bowel disease.- Enteral nutrition in inflammatory bowel disease.- Total parenteral nutrition in the management of inflammatory bowel disease: an update.- V: Medical management.- 5-ASA in ulcerative colitis.- 5-ASA preparations in the treatment of inflammatory bowel disease.- 4-amino salicylic acid in the treatment of ulcerative colitis: preliminary report of a randomized double-blind placebo controlled trial of oral 4-ASA.- Olsalazine (Dipentum(R)): the first choice in the treatment of ulcerative colitis.- Immunosuppressive drugs: do they have any role in the treatment of IBD? (A).- Immunosuppressive drugs: do they have any role in the treatment of IBD? (B).- Cyclosporin in inflammatory bowel disease.- Use of methotrexate for refractory inflammatory bowel disease.- Therapeutic strategies in IBD: Case discussion with computer-aided audience participation.- Index of subjects.